Developer docs
API playgroundTry for free, no card

Search company profiles

Aesculap Biologics

Full company profile

uuid000qdkl

Namestring
Aesculap Biologics
Websiteurl
aesculapbiologics.com
Company typeenum
Private
Founded yearint
1867
Short descriptiontext

Aesculap Biologics is a U.S.-based, privately held biologics company developing NOVOCART 3D, a 3D biological scaffold in clinical trials for treating knee cartilage defects, serving the orthobiologics market from Breinigsville, PA.

Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersBreinigsville, United States
HQ citystring
Breinigsville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
biological tissue repair, cartilage regeneration, orthopedic biologics, tissue engineering, regenerative medicine
Industry3 codes
1Cartilage, Bone & Musculoskeletal Regeneration
CodeHLAAAGAHPrimaryYes
2Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM)
CodeHLAHAEAGPrimaryNo
3Stem Cell Therapies (MSC/iPSC/HSC-derived)
CodeHLAAABAEPrimaryNo
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
Product category
Orthopedic Biologics
Social media profiles1 record
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Aesculap Biologics develops biological tissue repair therapies for orthopedic applications. Its lead program, NOVOCART 3D, is a tissue-engineered product in clinical trials intended for the treatment of knee cartilage defects, leveraging autologous chondrocyte transplantation technology.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1NOVOCART 3D
No data
Peers10 records
1Anika Therapeutics
TypeDirect peer
Description

Anika is a specialty orthobiologics company developing hyaluronic-acid-based and regenerative therapies for joints and soft tissue, directly comparable to Aesculap Biologics' cartilage and tissue repair focus.

2Arthrex
TypeDirect peer
Description

Arthrex is a leading orthopedic device and biologics company with a broad cartilage repair portfolio (e.g., autologous chondrocyte implantation, osteochondral autograft systems), competing in the same surgeon channels and knee cartilage repair indications.

3Stryker
TypeBroad incumbent
Description

Stryker's orthobiologics and sports medicine portfolio addresses cartilage and soft-tissue repair in the same end markets as Aesculap Biologics, though as part of a much broader orthopedic and surgical business.

4Vericel Corporation
TypeDirect peer
Description

Vericel markets MACI, an autologous cultured chondrocyte implant for knee cartilage defects—the most direct competitive therapy to Aesculap Biologics' NOVOCART 3D, serving the same orthopedic surgeons and patient population.

5CONMED
TypeBroad incumbent
Description

CONMED operates in sports medicine and orthopedics with cartilage repair and biologic adjunct products, competing in the same surgical specialties as Aesculap Biologics.

6CartiHeal (Smith & Nephew)
TypeEmerging player
Description

CartiHeal developed a cell-free, cartilage-implant technology for cartilage and osteochondral defects (acquired by Smith & Nephew); it represents an emerging technology pathway relevant to Aesculap Biologics' NOVOCART 3D development.

7Smith & Nephew
TypeBroad incumbent
Description

Smith & Nephew is a diversified orthopedic incumbent with established cartilage repair and orthobiologics offerings (including legacy Osiris Therapeutics assets), overlapping Aesculap Biologics in regenerative knee solutions at greater scale.

8Zimmer Biomet
TypeBroad incumbent
Description

Zimmer Biomet is a major orthopedic incumbent with biologics offerings in cartilage, bone graft substitutes, and sports medicine, making it a broad competitor in the orthobiologics space Aesculap Biologics occupies.

9Histogenics (now defunct / OCGN successor)
TypeEmerging player
Description

Histogenics developed NeoCart, an autologous chondrocyte-based implant for knee cartilage repair—one of the closest historical comparables to NOVOCART 3D—and illustrates both the opportunity and execution risk in this niche.

10B. Braun (parent ecosystem)
TypeOthers
Description

B. Braun is the Aesculap parent organization providing surgical, orthopedic, and biologics infrastructure; understanding B. Braun's broader portfolio and capital allocation is essential context for Aesculap Biologics' strategic position.

Market position
Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aesculap Biologics

Orthopedic Biologicsaesculapbiologics.com

Aesculap Biologics is a U.S.-based, privately held biologics company developing NOVOCART 3D, a 3D biological scaffold in clinical trials for treating knee cartilage defects, serving the orthobiologics market from Breinigsville, PA.

Aesculap Biologics firmographics

Firmographics
Name
Aesculap Biologics
Website
https://aesculapbiologics.com
Company type
Private
Founded year
1867
Headcount range
251–500 employees
Short description
Aesculap Biologics is a U.S.-based, privately held biologics company developing NOVOCART 3D, a 3D biological scaffold in clinical trials for treating knee cartilage defects, serving the orthobiologics market from Breinigsville, PA.
Ownership category
akta.pro rank

Aesculap Biologics industry classification

Industry
Product category
Orthopedic Biologics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
akta.pro primary industry
Cartilage, Bone & Musculoskeletal Regeneration (HLAAAGAH)
akta.pro secondary industries
Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM) (HLAHAEAG), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

Keywords

  • Biological tissue repair
  • Cartilage regeneration
  • Orthopedic biologics
  • Tissue engineering
  • Regenerative medicine

Where Aesculap Biologics is headquartered

Location

Headquarters

HQ city
Breinigsville
HQ country
United States
HQ region
North America

Markets served

Aesculap Biologics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Aesculap Biologics product offering

Product offering

Core offering

Aesculap Biologics develops biological tissue repair therapies for orthopedic applications. Its lead program, NOVOCART 3D, is a tissue-engineered product in clinical trials intended for the treatment of knee cartilage defects, leveraging autologous chondrocyte transplantation technology.

Differentiator

Problem solved

Functional benefit

Products and services

  • NOVOCART 3D

Companies that use Aesculap Biologics

Customer profile

Ideal customer profiles1 record

Aesculap Biologics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Aesculap Biologics competitors and assessment

Company assessment

Direct peers

  • Anika Therapeutics: Anika is a specialty orthobiologics company developing hyaluronic-acid-based and regenerative therapies for joints and soft tissue, directly comparable to Aesculap Biologics' cartilage and tissue repair focus.
  • Arthrex: Arthrex is a leading orthopedic device and biologics company with a broad cartilage repair portfolio (e.g., autologous chondrocyte implantation, osteochondral autograft systems), competing in the same surgeon channels and knee cartilage repair indications.
  • Vericel Corporation: Vericel markets MACI, an autologous cultured chondrocyte implant for knee cartilage defects—the most direct competitive therapy to Aesculap Biologics' NOVOCART 3D, serving the same orthopedic surgeons and patient population.

Broad incumbents

  • Stryker: Stryker's orthobiologics and sports medicine portfolio addresses cartilage and soft-tissue repair in the same end markets as Aesculap Biologics, though as part of a much broader orthopedic and surgical business.
  • CONMED: CONMED operates in sports medicine and orthopedics with cartilage repair and biologic adjunct products, competing in the same surgical specialties as Aesculap Biologics.
  • Smith & Nephew: Smith & Nephew is a diversified orthopedic incumbent with established cartilage repair and orthobiologics offerings (including legacy Osiris Therapeutics assets), overlapping Aesculap Biologics in regenerative knee solutions at greater scale.
  • Zimmer Biomet: Zimmer Biomet is a major orthopedic incumbent with biologics offerings in cartilage, bone graft substitutes, and sports medicine, making it a broad competitor in the orthobiologics space Aesculap Biologics occupies.

Emerging players

  • CartiHeal (Smith & Nephew): CartiHeal developed a cell-free, cartilage-implant technology for cartilage and osteochondral defects (acquired by Smith & Nephew); it represents an emerging technology pathway relevant to Aesculap Biologics' NOVOCART 3D development.
  • Histogenics (now defunct / OCGN successor): Histogenics developed NeoCart, an autologous chondrocyte-based implant for knee cartilage repair—one of the closest historical comparables to NOVOCART 3D—and illustrates both the opportunity and execution risk in this niche.

Others

  • B. Braun (parent ecosystem): B. Braun is the Aesculap parent organization providing surgical, orthopedic, and biologics infrastructure; understanding B. Braun's broader portfolio and capital allocation is essential context for Aesculap Biologics' strategic position.

Market position

Customer concentration

Aesculap Biologics social profiles

Digital presence

Aesculap Biologics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aesculap Biologics leadership team

Management profile

Number of profiles

Aesculap Biologics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aesculap Biologics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aesculap Biologics

What does Aesculap Biologics do?

Aesculap Biologics develops biological tissue repair therapies for orthopedic applications. Its lead program, NOVOCART 3D, is a tissue-engineered product in clinical trials intended for the treatment of knee cartilage defects, leveraging autologous chondrocyte transplantation technology.

When was Aesculap Biologics founded?

Aesculap Biologics was founded in 1867. It employs 251 to 500 people.

Where is Aesculap Biologics based?

Aesculap Biologics is headquartered in Breinigsville, United States, in the North America region.

Who are Aesculap Biologics's main competitors?

Direct peers on record are Anika Therapeutics, Arthrex and Vericel Corporation. Broad incumbents are Stryker, CONMED, Smith & Nephew and Zimmer Biomet. Emerging players are CartiHeal (Smith & Nephew) and Histogenics (now defunct / OCGN successor). B. Braun (parent ecosystem) is listed as an others.

Does Aesculap Biologics have an API?

No public API is recorded for Aesculap Biologics.

What industry is Aesculap Biologics in?

Aesculap Biologics's product category is Orthopedic Biologics. Its primary akta.pro industry code is HLAAAGAH, Cartilage, Bone & Musculoskeletal Regeneration, with a secondary code of HLAHAEAG, Bone Graft Substitutes & Orthobiologics (Synthetic/Allograft/DBM). Its NAICS code is 325414 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireScott Hacker, MD Treats his Tenth Patient in Pivotal Phase 3 Clinical Trial of NOVOCART® 3D in Patients with Articular Cartilage Defects of the KneeDr. Scott Hacker has treated his tenth patient in the ongoing Phase 3 clinical trial of NOVOCART® 3D, an investigational autologous chondrocyte transplantation system developed by Aesculap Biologics to treat articular cartilage defects of the knee. This pivotal multi-center study aims to confirm the product's clinical benefit and safety compared to microfracture, serving as the basis for its potential regulatory approval and launch in the U.S. market.PR NewswireAesculap Biologics, LLC Reaches Halfway Mark for Enrollment in Pivotal Phase 3 Clinical Trial of NOVOCART® 3D in Patients with Articular Cartilage Defects of the KneeAesculap Biologics announced it has reached 50% enrollment in its pivotal Phase 3 clinical trial for NOVOCART® 3D, treating approximately 117 of the expected 233 participants. The trial, active across more than 30 sites in the United States and Canada, aims to evaluate the safety and efficacy of the autologous chondrocyte transplantation system compared to Microfracture. Results from this study will serve as the basis for seeking regulatory approval for use of the product in the United States.PR NewswireAesculap Biologics Launches New WebsiteAesculap Biologics, LLC announced the launch of its redesigned website on December 11, 2017, featuring improved functionality and enhanced content for healthcare professionals and patients. The new website is designed to provide essential information about the NOVOCART 3D Phase 3 clinical trial, a tissue engineered cell-based product for repairing articular cartilage defects of the knee. The product originated in Europe where it has been implanted in more than 9,000 patients since 2003 and is currently seeking U.S. regulatory approval.